Nadolol is under clinical development by Invion and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Nadolol’s likelihood of approval (LoA) and phase transition for Asthma took place on 16 Feb 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Nadolol Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Nadolol (INV-102) is under development for the treatment of smoking cessation in a patient with chronic bronchitis, chronic obstructive pulmonary disease (COPD), cystic fibrosis and asthma. It is administered through oral and inhalational routes. It may be a steroid-sparing beta inverse agonist. Beta-blockers reduce the flow of air through the bronchial tubes in the lung. The drug candidate complements low-dose inhaled corticosteroids and improves the efficacy and safety of long-acting beta agonists.
It was also under development for the treatment of smoking cessation.
Invion is a life sciences company that develops products for the treatment of inflammatory diseases such as chronic inflammatory, airway disease and inflammation caused by autoimmune disease. The company’s pipeline products include INV102 nadolol, a beta adrenergic biased ligand targeted to reverse mucous metaplasia in the airway epithelium for the treatment of chronic inflammatory airway diseases; INV103 ala-Cpn10, a naturally occuring human protein for the treatment of chronic inflammation; and INV104 zafirlukast, a leukotriene receptor antagonist for the prevention of asthma attacks. Invion also conducts clinical development programs for developing zafirlukast as a novel non-steroidal, anti-inflammatory treatment to prevent asthma attacks. The company has operations in Melbourne, Australia and Delaware, the US. Invion is headquartered in Melbourne, Victoria, Australia.
Quick View Nadolol LOA Data
|Highest Development Stage|